Andrew is a Software Developer at RA Capital Management. Michael has more than two decades of experience in immuno-oncology and immunology research in both large pharma and biotech settings. Prior to Sage, he had a 14-year tenure at Biogen in various business and commercial roles. Joel brings 40 years of BioPharma drug discovery and development experience to that role. Brians primary responsibility at RA Capital is to conduct due diligence on biotechnology companies. Previously, Laura covered hematologic malignancies, cell therapies, retinal diseases, and orphan neurodevelopmental disorders. Peter has a BS in Biology with minors in both Chemistry and Spanish for the Medical Professions from the University of North Carolina at Chapel Hill. He was also a Board Member of the Fannie & John Hertz Foundation and served as a judge for the Lemelson-MIT StudentPrize for Inventorship. Peter Kolchinsky Net Worth (2023) | wallmine Dings primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Brian has more than ten years of buy-side experience covering the healthcare sector, with a focus on biotech, pharma, and specialty pharma. Tim began his career at Merck & Co., serving in multiple commercial roles in its cardiovascular, gastrointestinal, and managed care divisions. Jesse Chen is an EIR at RA Capital. His most recent role at Biogen was as Senior Vice President, U.S. Commercial, where he was the general manager of the MS, hemophilia, and SMA franchises. As Engagement Associate at RA Capital Management, Thomas Culman leverages qualitative and quantitative skills to manage a variety of educational, outreach, and advocacy-oriented projects. Garrett has worked cross-functionally across the landscape of in vivo and ex vivo genetic medicine modalities, often at the interface of payload design, platform research and manufacturing, IND-enabling activities, bioanalytical and computational biology, and strategy. After graduation he got $4 Million from Vertex Pharma co-founder Rich Aldrich and started picking biotech stocks at RA. Sadik Kassim is a scientist and executive with extensive experience in the biotechnology industry with a specific focus on cell and gene therapy bioprocessing and translational research. Most recently, Ally spent over five years at Akebia Therapeutics (previously Keryx), where she held Commercial Team Administrator/Internal Meetings Specialist, Sales Team Administrator/Training Specialist and Senior Administrative Assistant roles. Prior to Relay, she worked as an Executive Assistant at Bullhorn, Inc. Phi holds an Associate in Science Business Administration from Middlesex Community College. Ross primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Drinking, Drugs & Smoking Not present. Gunes conducts due diligence on biotechnology companies at RA Capital. Her graduate research investigated novel small molecule approaches to treating vestibular schwannoma and neurofibromatosis type 2. Jaimie has a BS in Marketing Management from Coastal Carolina University. Prior to Vor, Sadik served as Executive Director at Kite Pharma and led the development of manufacturing processes for autologous CAR-T and TCR-based cell therapies. Angela's primary responsibilities at RAVen are to lead development and oversee implementation of best practices in clinical strategies in RA's newcos and portfolio companies. Prior to RA, Elena gained analyst and research experience through roles with Alira Health, Mandarin Capital Partners, LifeLineLab S.r.l. Before her time at New Care, she was a Student Researcher at Boston Childrens Hospital Labs of Cognitive Neuroscience. Biohaven Closes Second Tranche Of Private Placement And Appoints Two While at Orbimed, he drove proprietary deal sourcing, diligence, negotiation, and investment decisions for growth stage companies and determined valuation ranges for companies and products with a focus on technology platform value, commercial potential, and binary catalysts such as clinical and regulatory milestones. Daniels primary responsibility at RA Capital is to edit and guide development of competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Gabes primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Mark brings to RAVen more than twenty-five years of leadership experience in the life sciences industryspanning operations, corporate development, legal affairs, and intellectual property. In his Venture role, Mario is focusing on early-stage investment and company creation. James Schneider is the Deputy General Counsel at RA Capital Management. Senior Research Assistant, Venture Analytics. Phi previously worked as an Executive Assistant at Relay Therapeutics. Brigid's primary responsibility at RA is to lead investments in private companies that are developing innovative solutions to address climate change and environmental sustainability. Chris Caliri is the Chief Information Officer at RA Capital Management. Kyle Teamey joins RA Capital as a Managing Partner, Planetary Health. Prior to her Managing Director role at NVF, Nandita held various positions at Novartis in Business Development and Licensing and as a key member of the Kymriah Global Program Team, helping to bring this novel cell therapy to market. Barrie's classic tale and has a somewhat dark look and feel. He previously worked as a Software Engineer for several companies, including Autodesk, the Advisory Board Company, and Maveric Systems. In this role, Maryann supports start-up business infrastructure development for newcos as well as provides strategic HR guidance for founding team members. He holds a BA in History from University of Massachusetts, Amherst and a Master's of Urban Affairs from Boston University. Sri Mahendra is a Senior Software Engineer at RA Capital Management. Prior to this role, Cristina mapped a number of competitive landscapes, including respiratory, allergic, and infectious disease conditions. Mario is responsible for partnering with several of our portfolio companies as Board Member or Technical Advisor. By Matt Grobar. Prior to KPMG, TJ worked within the AP/Office Admin function with the Boston Red Sox. In this role, he propelled the company to the next stage of growth and increased shareholder value by altering the course of this formerly research-based company to prioritize innovation, speed to commercialization, and culture transformation. EXCLUSIVE : Robert Morgan's Talaria . Michael has also previously held the position of Vice President and General Manager at Thomson Medstat (now part of IBM Watson Health), as well as held management roles at Immusol, a San Diego-based biotechnology company, HealthAllies, an organization created to provide discretionary medical benefits to the cash-pay market, and Da Vita, a national provider of dialysis services. James is admitted to practice law in the Commonwealth of Massachusetts. Astha is a Senior Data Analyst Associate at RA Capital Management. After joining RA Ventures as Chief Development Officer, Ed built the development team, oversaw development of six compounds from discovery-stage through to clinical-stage, and led the formation of several new companies, including Lusaris Therapeutics. Brett holds a BS from Washington University, St. Louis and a JD from Duquesne University School of Law and is admitted to practice law in PA. Brett previously served as a Clerk for the Washington County Court of Common Pleas in PA. Emilie Schleer is the Senior Investor Relations Manager with the Operations Team at RA Capital Management. In addition, Cosmas has co-founded companies including Design Pharma (synthetic bio) and a company in stealth focused on RNA based genetic medicines. Anurag holds a BSE in Biomedical Engineering and a BS in Economics from Duke University. But there are only so many vaccine experts. Currently, he serves as Chief Technology Officer at Danaher, with a focus on new genomic medicines. His laboratory at the Broad focused on advanced high throughput biotechnology tools including DNA synthesis, single cell analysis, synthetic biology derived biomolecule libraries, and microbiome profiling. Sarah Reed is the General Counsel at RA Capital Management. He co-founded and runs the Boston-based investment firm RA Capital Management; writes and teaches about biomedical entrepreneurship and its potential to transform global health; serves on the boards of several public and private drug development companies; and lives in Massachusetts with his historian/equestrian wife, strong-willed children, and reasonably well-trained dog. Pieter Boelhouwer is a Partner and Managing Director of Strategy and Operations at RA Capital Management. Prior to Bernstein, Joey held a Consultant role at FactSet. Tess has a BA with a double major in Economics and Peace & Conflict studies from the University of Toronto, Canada. Kriti holds a B.S. Before transitioning to industry, Cosmas was a faculty member at Harvard Medical School/Massachusetts General Hospital (MGH), where he had an active gastroenterology clinical practice and ran a lab whose research centered on fundamental aspects of RNA and epigenetics. She has published over fifty papers in peer reviewed journals. Founders GSAS Harvard Biotech Club Dr. Kolchinsky is a founding Partner and Portfolio Manager at RA Capital. Her graduate research investigated novel epigenetic regulators in glioblastoma. Kevin's primary responsibilities is to research early-stage projects in collaboration with RAVen team members, Venture Partners, and Entrepreneurs-in-Residence. His graduate research focused on identifying novel targets for disrupting the cell cycle in cancer cells. Joey holds a Bachelor of Science in Finance from American University and is FINRA-certified in Series 7, Series 63 and Securities Industry Essentials. Josh holds a BS in Genetics, Genomics, and Biotechnology with a Minor in Business from Brigham Young University. Prior to Flywire, she worked as an Executive/Personal Assistant at Spark Capital. Prior to joining RA, Michael was Associate Vice President at Merck Research Labs. Josh was previously co-lead of SV Health Investors US Biotech practice where he was responsible for SVs US venture creation activities, including its incubator, Brahma Discovery. He worked previously as the Director of Business Systems at Bain Capital Credit, and as a Senior Systems Analyst at eSecLending, LLC. Michael is the Chief Financial Officer at RA Capital Management. He is a member of the Advisory Boards of the Applied Biotechnology Laboratory at the Francis Crick Institute, the Center for Surgery,Innovation & Bioengineering at the Massachusetts General Hospital/Harvard MedicalSchool; the Chemical& Biomolecular Engineering Department of the University of Illinois and the Biomedical Engineering Departmentof Rutgers University. Matthew holds a BS in Environmental Health Science from the University of Georgia and both a PhD in Biomedical Science and an MBA with a concentration in Finance from the University of Connecticut. She holds a BS in Corporate Finance & Accounting and an MBA from Salem State University. Joshs primary responsibility at RA Capital is to lead early-stage private investments in and oversee the creation of new companies developing drugs, medical devices, diagnostics, and research tools. Angela Pontius is Vice President of Clinical Operations at RA Ventures (RAVen). Rezs primary responsibility is to lead early-stage private investments in, and oversee the creation of, new companies developing therapeutics and other medical technologies. Prior to joining RA, Nadim was at NYU School of Medicine as Associate Dean of Therapeutics Alliances, a drug discovery accelerator that de-risks academic research towards partnerships with biopharma, investors, and nonprofits. Soumya has more than two decades of experience in structure-based drug design and molecular modeling both in the areas of small molecules and biologics across multiple target classes and indications. Brendan is a Tax Director at RA Capital Management. Prior to Mirai Advisory, he held a Financial Analyst role at Wainwright Investment Counsel. According to Famous Birthdays, Peter was born on June 14, 1984, which makes him 38 years old, going on 39 in 2023. Angela has a BA in Pre-Medicine and French Studies from the University of Minnesota. Mariagrace has a BS in Sociology from Suffolk University. Before SV, Josh was President and Managing Partner at MRL Ventures Fund, the early-stage therapeutics-focused corporate venture fund within Merck & Co. BioVentures. Prior to this, she served as Director, Talent Acquisition and Operations at Flagship Pioneering, a role in which she built talent systems to support the growth of 30+ pre-series B biotech startup companies. Rez Halse is President of RAVen, also known as RA Ventures, RA Capitals company creation incubator. Prior to joining biotech/pharma, she was a specialist in the corporate finance team at McKinsey & Co, focused on corporate transactions. Brackett Hardy is a Junior Associate with the TechAtlas division of RA Capital Management. Mario received postdoctoral training at the NIH and Mount Sinai School of Medicine in innate immunity and bioinformatics, earned a PhD in microbiology at University of Chile and a MS in Nuclear Physics. Raj is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. Sarah began her legal career with Foley, Hoag, & Eliot LLP. Peter Pan & Wendy Movie Review | Common Sense Media Beginning in 2012, and prior to joining the Investment Manager, he was a Vice President at H.I.G. Brigid was responsible for starting the venture fund and led investments in multiple sectors, including advanced analytics platforms, biomining and bioremediation, novel chemical leaching, long-duration energy storage, traceability of products, carbon removal, and green steel. Laura works on both public and private investments and serves as a Board Director for Artiva Biotherapeutics, Nimbus Therapeutics, and Acumen Pharmaceuticals. James McArthur is an Advisor for RA Capital Management. Nate Davis is an Analyst on the Investment Team at RA Capital Management. Becca has a BA in Biology from Colgate University and a PhD in Biology from MIT. He holds a Masters degree in Software Engineering from Brandeis University and a BA in Psychology from Providence College. Joe holds a BS in Information Technology from UMass Lowell. Prior to PwC, Brendan worked as Senior Tax Analyst for Highfields Capital Management LP and held tax and accounting positions at Citi and Investors Bank & Trust / State Street.
Male Celebrities Who Part Their Hair On The Right,
Applebee's Ashland Menu,
Old Yankee Stadium Address,
Minecraft Decimation How To Drink Water,
Articles P
